Amgen's Q2 earnings call revealed a strong quarterly performance, with 13% revenue growth and 34% adjusted EPS growth. The company raised its 2012 guidance for revenues and EPS, driven by the strong performance of its established products, including Enbrel, and the success of its newly launched products, such as XGEVA and Prolia. Management's tone was positive, highlighting the company's execution on its growth strategy and the momentum in its business. The company also provided updates on its pipeline, including the progress of its PCSK9 antibody, AMG 145, and its sclerostin antibody, AMG 785. Overall, the call suggested a positive outlook for the company's short-term performance.

[1]